Selected research
Market Structure
Global Spasmolytic Injections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Spasmolytic Injections market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Spasmolytic Injections include AdvaCare Pharma, Allergan, Baxter International, Boehringer Ingelheim, Chengdu Better Pharmaceutical, CNS Therapeutics, Huarun Shuanghe, Ipsen and Medytox, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Spasmolytic Injections market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Spasmolytic Injections and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Spasmolytic Injections revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Spasmolytic Injections market size, projected growth trends, production technologies, key applications, and end-use industries.
Spasmolytic Injections Segment by Company
AdvaCare Pharma
Allergan
Baxter International
Boehringer Ingelheim
Chengdu Better Pharmaceutical
CNS Therapeutics
Huarun Shuanghe
Ipsen
Medytox
Nanjing Hangsheng Pharmaceutical
Sun Pharmaceutical Industries
Wanbangde Pharmaceutical Group
Wuhan Renfu Pharmaceutical
Zydus Cadila
Lilly
Mylan
Sanofi
Teva Pharmaceuticals
Spasmolytic Injections Segment by Type
Papaverines
Anticholinergics
Calcium Channel Blockers
Others
Spasmolytic Injections Segment by Application
Hospital
Clinic
Spasmolytic Injections Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spasmolytic Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Spasmolytic Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spasmolytic Injections.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Spasmolytic Injections in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Spasmolytic Injections industry.
Chapter 3: Detailed analysis of Spasmolytic Injections companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Spasmolytic Injectionsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Papaverines
- Anticholinergics
- Calcium Channel Blockers
- Others
Applications
- Hospital
- Clinic
Companies covered
- AdvaCare Pharma
- Allergan
- Baxter International
- Boehringer Ingelheim
- Chengdu Better Pharmaceutical
- CNS Therapeutics
- Huarun Shuanghe
- Ipsen
- Medytox
- Nanjing Hangsheng Pharmaceutical
- Sun Pharmaceutical Industries
- Wanbangde Pharmaceutical Group
- Wuhan Renfu Pharmaceutical
- Zydus Cadila
- Lilly
- Mylan
- Sanofi
- Teva Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Spasmolytic Injections Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Papaverines
- 1.2.3 Anticholinergics
- 1.2.4 Calcium Channel Blockers
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Spasmolytic Injections Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.4 Global Market Growth Prospects
- 1.5 Global Spasmolytic Injections Growth Trends by Region
- 1.5.1 Global Spasmolytic Injections Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Spasmolytic Injections Market Size by Region (2021-2026)
- 1.5.3 Spasmolytic Injections Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Spasmolytic Injections Market Dynamics
- 2.1 Spasmolytic Injections Industry Trends
- 2.2 Spasmolytic Injections Industry Drivers
- 2.3 Spasmolytic Injections Industry Opportunities and Challenges
- 2.4 Spasmolytic Injections Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Spasmolytic Injections Revenue by Company (2021-2026)
- 3.2 Global Spasmolytic Injections Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Spasmolytic Injections Key Company Head office and Area Served
- 3.4 Global Spasmolytic Injections Company, Product Type & Application
- 3.5 Global Spasmolytic Injections Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Spasmolytic Injections Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Spasmolytic Injections Players Market Share by Revenue in 2025
- 3.6.3 2025 Spasmolytic Injections Tier 1, Tier 2, and Tier 3
4 Spasmolytic Injections Market by Type
- 4.1 Global Spasmolytic Injections Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Spasmolytic Injections Market Size by Type (2021-2032)
- 4.3 Global Spasmolytic Injections Market Size Share by Type (2021-2032)
5 Spasmolytic Injections Market by Application
- 5.1 Global Spasmolytic Injections Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Spasmolytic Injections Market Size by Application (2021-2032)
- 5.3 Global Spasmolytic Injections Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 AdvaCare Pharma
- 6.1.1 AdvaCare Pharma Company Information
- 6.1.2 AdvaCare Pharma Business Overview
- 6.1.3 AdvaCare Pharma Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 AdvaCare Pharma Spasmolytic Injections Product Portfolio
- 6.1.5 AdvaCare Pharma Recent Developments
- 6.2 Allergan
- 6.2.1 Allergan Company Information
- 6.2.2 Allergan Business Overview
- 6.2.3 Allergan Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Allergan Spasmolytic Injections Product Portfolio
- 6.2.5 Allergan Recent Developments
- 6.3 Baxter International
- 6.3.1 Baxter International Company Information
- 6.3.2 Baxter International Business Overview
- 6.3.3 Baxter International Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Baxter International Spasmolytic Injections Product Portfolio
- 6.3.5 Baxter International Recent Developments
- 6.4 Boehringer Ingelheim
- 6.4.1 Boehringer Ingelheim Company Information
- 6.4.2 Boehringer Ingelheim Business Overview
- 6.4.3 Boehringer Ingelheim Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Boehringer Ingelheim Spasmolytic Injections Product Portfolio
- 6.4.5 Boehringer Ingelheim Recent Developments
- 6.5 Chengdu Better Pharmaceutical
- 6.5.1 Chengdu Better Pharmaceutical Company Information
- 6.5.2 Chengdu Better Pharmaceutical Business Overview
- 6.5.3 Chengdu Better Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio
- 6.5.5 Chengdu Better Pharmaceutical Recent Developments
- 6.6 CNS Therapeutics
- 6.6.1 CNS Therapeutics Company Information
- 6.6.2 CNS Therapeutics Business Overview
- 6.6.3 CNS Therapeutics Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 CNS Therapeutics Spasmolytic Injections Product Portfolio
- 6.6.5 CNS Therapeutics Recent Developments
- 6.7 Huarun Shuanghe
- 6.7.1 Huarun Shuanghe Company Information
- 6.7.2 Huarun Shuanghe Business Overview
- 6.7.3 Huarun Shuanghe Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Huarun Shuanghe Spasmolytic Injections Product Portfolio
- 6.7.5 Huarun Shuanghe Recent Developments
- 6.8 Ipsen
- 6.8.1 Ipsen Company Information
- 6.8.2 Ipsen Business Overview
- 6.8.3 Ipsen Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Ipsen Spasmolytic Injections Product Portfolio
- 6.8.5 Ipsen Recent Developments
- 6.9 Medytox
- 6.9.1 Medytox Company Information
- 6.9.2 Medytox Business Overview
- 6.9.3 Medytox Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Medytox Spasmolytic Injections Product Portfolio
- 6.9.5 Medytox Recent Developments
- 6.10 Nanjing Hangsheng Pharmaceutical
- 6.10.1 Nanjing Hangsheng Pharmaceutical Company Information
- 6.10.2 Nanjing Hangsheng Pharmaceutical Business Overview
- 6.10.3 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio
- 6.10.5 Nanjing Hangsheng Pharmaceutical Recent Developments
- 6.11 Sun Pharmaceutical Industries
- 6.11.1 Sun Pharmaceutical Industries Company Information
- 6.11.2 Sun Pharmaceutical Industries Business Overview
- 6.11.3 Sun Pharmaceutical Industries Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio
- 6.11.5 Sun Pharmaceutical Industries Recent Developments
- 6.12 Wanbangde Pharmaceutical Group
- 6.12.1 Wanbangde Pharmaceutical Group Company Information
- 6.12.2 Wanbangde Pharmaceutical Group Business Overview
- 6.12.3 Wanbangde Pharmaceutical Group Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio
- 6.12.5 Wanbangde Pharmaceutical Group Recent Developments
- 6.13 Wuhan Renfu Pharmaceutical
- 6.13.1 Wuhan Renfu Pharmaceutical Company Information
- 6.13.2 Wuhan Renfu Pharmaceutical Business Overview
- 6.13.3 Wuhan Renfu Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio
- 6.13.5 Wuhan Renfu Pharmaceutical Recent Developments
- 6.14 Zydus Cadila
- 6.14.1 Zydus Cadila Company Information
- 6.14.2 Zydus Cadila Business Overview
- 6.14.3 Zydus Cadila Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Zydus Cadila Spasmolytic Injections Product Portfolio
- 6.14.5 Zydus Cadila Recent Developments
- 6.15 Lilly
- 6.15.1 Lilly Company Information
- 6.15.2 Lilly Business Overview
- 6.15.3 Lilly Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Lilly Spasmolytic Injections Product Portfolio
- 6.15.5 Lilly Recent Developments
- 6.16 Mylan
- 6.16.1 Mylan Company Information
- 6.16.2 Mylan Business Overview
- 6.16.3 Mylan Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Mylan Spasmolytic Injections Product Portfolio
- 6.16.5 Mylan Recent Developments
- 6.17 Sanofi
- 6.17.1 Sanofi Company Information
- 6.17.2 Sanofi Business Overview
- 6.17.3 Sanofi Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Sanofi Spasmolytic Injections Product Portfolio
- 6.17.5 Sanofi Recent Developments
- 6.18 Teva Pharmaceuticals
- 6.18.1 Teva Pharmaceuticals Company Information
- 6.18.2 Teva Pharmaceuticals Business Overview
- 6.18.3 Teva Pharmaceuticals Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Teva Pharmaceuticals Spasmolytic Injections Product Portfolio
- 6.18.5 Teva Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Spasmolytic Injections Market Size (2021-2032)
- 7.2 North America Spasmolytic Injections Market Size by Type
- 7.2.1 North America Spasmolytic Injections Market Size by Type (2021-2026)
- 7.2.2 North America Spasmolytic Injections Market Size by Type (2027-2032)
- 7.2.3 North America Spasmolytic Injections Market Share by Type (2021-2032)
- 7.3 North America Spasmolytic Injections Market Size by Application
- 7.3.1 North America Spasmolytic Injections Market Size by Application (2021-2026)
- 7.3.2 North America Spasmolytic Injections Market Size by Application (2027-2032)
- 7.3.3 North America Spasmolytic Injections Market Share by Application (2021-2032)
- 7.4 North America Spasmolytic Injections Market Size by Country
- 7.4.1 North America Spasmolytic Injections Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Spasmolytic Injections Market Size by Country (2021-2026)
- 7.4.3 North America Spasmolytic Injections Market Size by Country (2027-2032)
- 7.4.4 North America Spasmolytic Injections Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Spasmolytic Injections Market Size (2021-2032)
- 8.2 Europe Spasmolytic Injections Market Size by Type
- 8.2.1 Europe Spasmolytic Injections Market Size by Type (2021-2026)
- 8.2.2 Europe Spasmolytic Injections Market Size by Type (2027-2032)
- 8.2.3 Europe Spasmolytic Injections Market Share by Type (2021-2032)
- 8.3 Europe Spasmolytic Injections Market Size by Application
- 8.3.1 Europe Spasmolytic Injections Market Size by Application (2021-2026)
- 8.3.2 Europe Spasmolytic Injections Market Size by Application (2027-2032)
- 8.3.3 Europe Spasmolytic Injections Market Share by Application (2021-2032)
- 8.4 Europe Spasmolytic Injections Market Size by Country
- 8.4.1 Europe Spasmolytic Injections Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Spasmolytic Injections Market Size by Country (2021-2026)
- 8.4.3 Europe Spasmolytic Injections Market Size by Country (2027-2032)
- 8.4.4 Europe Spasmolytic Injections Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Spasmolytic Injections Market Size (2021-2032)
- 9.2 China Spasmolytic Injections Market Size by Type
- 9.2.1 China Spasmolytic Injections Market Size by Type (2021-2026)
- 9.2.2 China Spasmolytic Injections Market Size by Type (2027-2032)
- 9.2.3 China Spasmolytic Injections Market Share by Type (2021-2032)
- 9.3 China Spasmolytic Injections Market Size by Application
- 9.3.1 China Spasmolytic Injections Market Size by Application (2021-2026)
- 9.3.2 China Spasmolytic Injections Market Size by Application (2027-2032)
- 9.3.3 China Spasmolytic Injections Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Spasmolytic Injections Market Size (2021-2032)
- 10.2 Asia Spasmolytic Injections Market Size by Type
- 10.2.1 Asia Spasmolytic Injections Market Size by Type (2021-2026)
- 10.2.2 Asia Spasmolytic Injections Market Size by Type (2027-2032)
- 10.2.3 Asia Spasmolytic Injections Market Share by Type (2021-2032)
- 10.3 Asia Spasmolytic Injections Market Size by Application
- 10.3.1 Asia Spasmolytic Injections Market Size by Application (2021-2026)
- 10.3.2 Asia Spasmolytic Injections Market Size by Application (2027-2032)
- 10.3.3 Asia Spasmolytic Injections Market Share by Application (2021-2032)
- 10.4 Asia Spasmolytic Injections Market Size by Country
- 10.4.1 Asia Spasmolytic Injections Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Spasmolytic Injections Market Size by Country (2021-2026)
- 10.4.3 Asia Spasmolytic Injections Market Size by Country (2027-2032)
- 10.4.4 Asia Spasmolytic Injections Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Spasmolytic Injections Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Spasmolytic Injections Market Size by Type
- 11.2.1 South America, Middle East & Africa Spasmolytic Injections Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Spasmolytic Injections Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Spasmolytic Injections Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Spasmolytic Injections Market Size by Application
- 11.3.1 South America, Middle East & Africa Spasmolytic Injections Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Spasmolytic Injections Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Spasmolytic Injections Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Spasmolytic Injections Market Size by Country
- 11.4.1 South America, Middle East & Africa Spasmolytic Injections Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Spasmolytic Injections Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Spasmolytic Injections Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Spasmolytic Injections Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst